Thrilled to share our latest study in Nature Cancer investigating the diverse malignant and stromal cell states that make up soft tissue #sarcomas (STS) and their associations with patient outcomes and response to treatment! 1/12 nature.com/articles/s4301…

A deep PSA nadir to <0.1ng/ml within 6mths of RT completion is highly prognostic for metastasis-free survival, prostate cancer mortality and overall survival in men receiving RT and ADT for M0 prostate cancer - work from #ICECAP published in Journal of Clinical Oncology: ascopubs.org/doi/10.1200/JC…

#BCR #ProstateCancer in the era of #EMBARK & #PSMA imaging: Everything has changed, EXCEPT the pts 🚨New tech & data does not drastically alter fundamentals of BCR care Now more than ever, BCR pts require a thoughtful approach to avoid overtreatment shorturl.at/gqAPQ

This is the kind of communication that’s so essential at the first encounter, yet often so hard to fit into multiD clinics built as a pipeline. Important to know when to hit the “pause” button, listen, schedule follow-ups, etc.

Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC Wenxin (Vincent) Xu Dana-Farber @Harvardmed @gotoper #gotoPER #NYGU #kcsm onclive.com/view/establish…

Featured on WBZ NewsRadio - Dana-Farber's Ben Schlechter, MD, (Ben Schlechter) discusses the role of DNA, RNA, the microbiome, diet, and exercise in the rising rate of young-onset colorectal cancer. CC: Dana-Farber's Young-Onset Colorectal Cancer Center Listen to the segment here: ms.spr.ly/6011cIoBz

I am sincerely humbled by this recognition. Deeply grateful to all my collaborators, mentors, and specially my fabulous team! BCM Department of Medicine From the Labs at Baylor College of Medicine Dan L Duncan Comprehensive Cancer Center BCMHouston

1/ Excited to share our data at #AACR2024: KIM-1 and PD-L1 enrich for benefit from adj ipi+nivo in CM-914 Part A. High (Q4) baseline KIM-1 had worse DFS, but this risk was mitigated by ipi+nivo.

nature.com/articles/s4159… fantastic innovation for refractory #colorectalcancer ⁦Dana-Farber⁩ ⁦Dana-Farber's Young-Onset Colorectal Cancer Center⁩ ⁦Dana-Farber News⁩ ⁦BIDMC⁩ ⁦Anthony El-Khoueiry⁩ ⁦Dr. Marwan G. Fakih⁩ ⁦Bruno Bockorny MD FACP⁩ ⁦Agenus⁩

Does the presence of DDR alterations impact outcomes to LuPSMA in mCRPC? Check out our work led by Harvard Medical School students Avina Rami Narmeen Rashid published in ESMO Open: authors.elsevier.com/sd/article/S20… Dana-Farber Lank Center for Genitourinary Oncology Alok Tewari

Our very own Praful Ravi discussing post-RLT monitoring - a key consideration as the use of these agents grows in clinical practice Dana-Farber Dana-Farber Lank Center for Genitourinary Oncology

This summer: OncLive.com State of the Science Summit on GU malignancies. Collaborative across Dana-Farber/Harvard Cancer Center programs, featuring from the Lank Center Alicia Morgans, MD, MPH on prostate cancer and Wenxin (Vincent) Xu on kidney cancer. More info in the flyer below 👇

We worked together with Sadeem Ahmad, Sun Hur, and others to understand how the PACT protein prevents the activation of the double-stranded RNA sensor PKR by endogenous cellular RNAs. nature.com/articles/s4146…

🚨 Proud to share our recent paper on virtual second opinions for cancer care Stanford Cancer Institute. Changes in management were recommended in >50% of cases. Many of these opinions were associated with: 1. de-escalation of care - e.g NOT recommending adjuvant chemotherapy for

Most viewed this week from JAMA Oncology: Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy. ja.ma/44fFHqa

Prostate cancer at #ASCO25: Talazoparib + tazemetostat showed expected bone marrow suppression & limited benefit in pre-treated, biomarker-unselected patients. Research underway to ID those most likely to respond. Atish Choudhury, MD PhD Dana-Farber Lank Center for Genitourinary Oncology

I think this might be my best slide yet… #IYKYK Prostate Cancer Foundation

1/5 This comes up in #kidneycancer clinic every few months. And on patient groups just as often. 📊 The ASSURE nomogram shows cumulative disease-free survival (DFS) from time 0 after surgery. Great info… until someone hits the 2-year mark and panics at that 48.8% 3-year number.

Diagnosis of iron deficiency in patients with cancer requires different thresholds. Excellent review from the BIDMC hematology team. Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice ascopubs.org/doi/abs/10.120…

Check our latest work on #testicularcancer published Histopathology 🔬onlinelibrary.wiley.com/doi/10.1111/hi… #pathtwitter GU Pathology Society (GUPS) International Society of Urological Pathology YAU Working Group Penile & Testis Cancer European Society of Pathology (ESP) IPO Porto USCAP Cancer Biology & Epigenetics Group_IPO Porto #microrna371 Andres Martin Acosta (Andy) Instituto de Ciências Biomédicas Abel Salazar UP European Association of Urology (EAU) Testicular Cancer